Aurora Cannabis sees positive adjusted EBITDA in Q3

“In Q3 2025, we expect to see continued strong net revenue and adjusted gross margins across our global medical cannabis business, supported by net revenue1 growth in Europe and Australia. For plant propagation, we expect to see seasonally reduced net revenues and adjusted gross profit1 that will be in line with historical seasonal trends as 25%-35% of revenues are normally earned in the second half of a calendar year. Positive adjusted EBITDA is expected to continue, while free cash flow is projected to be positive due to strong net revenue and continued spend discipline, resulting in strong adjusted gross margins.”